{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:28:41Z","timestamp":1788366521675,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.acuroe.2024.09.005","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:56:44Z","timestamp":1727398604000},"page":"718-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"48","author":[{"given":"\u00d3.","family":"Rodr\u00edguez Faba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Fern\u00e1ndez G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"\u00c1lvarez-Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Ledo Cepero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Unda Urzaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mart\u00ednez-Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"C\u00f3zar Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Palou","family":"Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"\u00c1lvarez-Ossorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.acuroe.2024.09.005_bib0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0010","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(69)92648-8","article-title":"Active immunotherapy for acute lymphoblastic leukaemia","volume":"1","author":"Mathe","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0015","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00000658-197010000-00018","article-title":"Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy","volume":"172","author":"Morton","year":"1970","journal-title":"Ann Surg"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0020","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.juro.2016.10.101","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"197","author":"Morales","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0025","first-page":"250","article-title":"BCG shortage for intravesical instillation is associated with early tumoral recurrence in patients with high-risk non-muscle invasive bladder tumours","volume":"47","author":"Perez-Aizpurua","year":"2023","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0030","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Guerin Connaught strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0040","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and update for S1602 \"A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naive High-grade Non-muscle-invasive Bladder Cancer\u201d","volume":"4","author":"Svatek","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clgc.2019.10.021","article-title":"Comparative effectiveness of intravesical BCG-tice and BCG-Moreau in patients with non-muscle-invasive bladder cancer","volume":"18","author":"D\u2019Andrea","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0050","first-page":"387","article-title":"Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert\u2019s panel. Spanish Association of Urology","volume":"37","author":"Fernandez-Gomez","year":"2013","journal-title":"Actas Urol Esp"},{"issue":"Suppl 3","key":"10.1016\/j.acuroe.2024.09.005_bib0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000052388","article-title":"Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use","volume":"37","author":"Schamhart","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0060","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030357","article-title":"New perspectives in the medical treatment of non-muscle-invasive bladder cancer: immune checkpoint inhibitors and beyond","volume":"11","author":"Audisio","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0070","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0075","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","article-title":"A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder","volume":"153","author":"Vegt","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0090","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.acuro.2017.10.003","article-title":"Safety and efficacy of various strains of bacille Calmette-Guerin in the treatment of bladder tumours in standard clinical practice","volume":"42","author":"Unda-Urzaiz","year":"2018","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0095","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008300","article-title":"Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials","volume":"96","author":"Quan","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0105","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0110","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0120","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0125","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0130","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003361.03","article-title":"LBA02-03 - first results from SunRISe-1 in patients with BCG unresponsive high-risk non\u2013muscle-invasive bladder cancer receiving TAR-200 in combination with Cetrelimab, TAR-200, or Cetrelimab alone","volume":"209","author":"Daneshmand","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette-Guerin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0140","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and Update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical Bacillus Calmette-Guerin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-naive High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0145","article-title":"Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.acuroe.2024.09.005_bib0150","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.euo.2023.09.014","article-title":"A territory-wide study investigating the dose and efficacy of different bacillus Calmette-Guerin strains in patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"7","author":"Liu","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0155","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.acuro.2017.03.003","article-title":"Adjuvant intravesical treatment for nonmuscle invasive bladder cancer: the importance of the strain and maintenance","volume":"41","author":"Guerrero-Ramos","year":"2017","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0160","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.acuro.2022.06.001","article-title":"Reduced- vs full-dose BCG in bladder cancer: a systematic review and meta-analysis","volume":"47","author":"Verri","year":"2023","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00345-009-0389-x","article-title":"Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer","volume":"27","author":"Di Stasi","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0185","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0190","first-page":"93","article-title":"Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)","volume":"45","author":"Alvarez-Maestro","year":"2021","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0195","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0200","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0205","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0210","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0220","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.acuro.2022.01.002","article-title":"Surveillance and office management of low-grade Ta bladder tumors","volume":"46","author":"Lokeshwar","year":"2022","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0225","first-page":"647","article-title":"Risk estimation of multiple recurrence and progression of non muscle invasive bladder carcinoma using new mathematical models","volume":"38","author":"Lujan","year":"2014","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0230","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/his.14764","article-title":"What\u2019s new in WHO fifth edition - urinary tract","volume":"81","author":"Comperat","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0235","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0240","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0245","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0250","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0255","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0260","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them","volume":"149","author":"Koch","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0275","first-page":"604","article-title":"Surveillance of the safety of intravesical BCG therapy in France: quantitative analysis of serious adverse events notified over a period of five years","volume":"12","author":"Debois","year":"2002","journal-title":"Prog Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0280","first-page":"4927","article-title":"Intravesical therapy use in the high risk patient: practice patterns in an equal access healthcare institution before and after national guidelines","volume":"16","author":"Pugliese","year":"2009","journal-title":"Can J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0285","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","article-title":"Complications of intravesical chemotherapy","volume":"19","author":"Thrasher","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0290","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.juro.2012.10.070","article-title":"Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guerin treatment","volume":"189","author":"Johnson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0295","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0300","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1023\/A:1019507104741","article-title":"Intravesical treatment of severe bacillus Calmette-Guerin cystitis","volume":"33","author":"Palou","year":"2001","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0305","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0022-5347(05)68961-6","article-title":"Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail","volume":"161","author":"Wittes","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0310","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.acuro.2022.08.001","article-title":"Evaluation of incidence, predictive factors and treatment considerations for asymptomatic genitourinary granulomas after intravesical bacillus Calmette-Guerin therapy","volume":"47","author":"Soda","year":"2023","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0315","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3348\/kjr.2015.16.2.342","article-title":"Multiphase contrast-enhanced magnetic resonance imaging features of Bacillus Calmette-Guerin-induced granulomatous prostatitis in five patients","volume":"16","author":"Kawada","year":"2015","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0320","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5301\/uro.5000189","article-title":"The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer","volume":"83","author":"Serretta","year":"2016","journal-title":"Urologia"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0325","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0094-0143(21)00423-7","article-title":"Complications of bacillus Calmette-Guerin immunotherapy","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0330","first-page":"16","article-title":"\"BCGitis\": a rare case of tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guerin therapy","volume":"6","author":"Demers","year":"2012","journal-title":"J Radiol Case Rep"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0335","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0022-5347(05)64751-9","article-title":"Optimal treatment of systemic bacillus Calmette-Guerin infection: investigations in an animal model","volume":"168","author":"Durek","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0340","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.revmed.2010.01.010","article-title":"Acute reactive arthritis after intravesical instillation of bacillus Calmette-Guerin. Two case reports and literature review","volume":"31","author":"Miranda","year":"2010","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.acuroe.2024.09.005_bib0345","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00296-005-0059-2","article-title":"Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review","volume":"26","author":"Tinazzi","year":"2006","journal-title":"Rheumatol Int"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T23:39:39Z","timestamp":1734046779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578624001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2173578624001094"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.09.005","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2024.06.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}